全文获取类型
收费全文 | 428篇 |
免费 | 22篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 4篇 |
妇产科学 | 15篇 |
基础医学 | 32篇 |
口腔科学 | 24篇 |
临床医学 | 26篇 |
内科学 | 93篇 |
皮肤病学 | 6篇 |
神经病学 | 10篇 |
特种医学 | 24篇 |
外科学 | 88篇 |
综合类 | 4篇 |
预防医学 | 20篇 |
眼科学 | 7篇 |
药学 | 6篇 |
中国医学 | 3篇 |
肿瘤学 | 84篇 |
出版年
2023年 | 3篇 |
2022年 | 6篇 |
2021年 | 18篇 |
2020年 | 11篇 |
2019年 | 69篇 |
2018年 | 56篇 |
2017年 | 46篇 |
2016年 | 4篇 |
2015年 | 5篇 |
2014年 | 13篇 |
2013年 | 11篇 |
2012年 | 3篇 |
2011年 | 2篇 |
2010年 | 2篇 |
2009年 | 2篇 |
2008年 | 4篇 |
2007年 | 1篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2001年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1987年 | 1篇 |
1985年 | 21篇 |
1984年 | 32篇 |
1983年 | 24篇 |
1982年 | 15篇 |
1981年 | 6篇 |
1980年 | 18篇 |
1979年 | 18篇 |
1978年 | 11篇 |
1977年 | 6篇 |
1976年 | 4篇 |
1975年 | 7篇 |
1974年 | 8篇 |
1973年 | 11篇 |
排序方式: 共有450条查询结果,搜索用时 15 毫秒
1.
Sen Pathak 《Cancer Genetics and Cytogenetics》1980,1(3):281-289
Cytogenetic analysis using C-, G-, and Ag-nucleolus organizer region (NOR) staining techniques, performed on established cell lines as well as directly processed breast tumor effusions, revealed that: 1) chromosome No. 1 is involved in translocation; 2) based on 1q translocation chromosome, breast tumors could be classified into two groups; and 3) double minutes and homogeneously staining regions may be present in breast tumor cells in vivo as well as in vitro, and that homogeneously staining regions may exhibit some heterogeneity in staining. 相似文献
2.
3.
4.
《Alcoholism treatment quarterly》2013,31(1):115-124
No abstract available for this article. 相似文献
5.
Jessica G.Y. Luc Michael A. Archer Rakesh C. Arora Edward M. Bender Arie Blitz David T. Cooke Tamara Ni Hlci Biniam Kidane Maral Ouzounian Thomas K. Varghese Mara B. Antonoff 《The Annals of thoracic surgery》2021,111(1):296-300
- Download : Download high-res image (181KB)
- Download : Download full-size image
6.
7.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
8.
9.
10.